Get the Stockscreener App
32.82
3.60%
1.14
After Hours:
32.82
Supernus Pharmaceuticals Inc stock is traded at $32.82, with a volume of 373.12K.
It is up +3.60% in the last 24 hours and up +2.37% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$31.68
Open:
$31.42
24h Volume:
373.12K
Relative Volume:
0.71
Market Cap:
$1.77B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
30.68
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+1.52%
1M Performance:
+2.37%
6M Performance:
+2.05%
1Y Performance:
-1.06%
1-Day Range:
$31.13
$32.93
1-Week Range:
$31.13
$32.93
52-Week Range:
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
32.82 | 1.77B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Several Supernus Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by HighTower Advisors LLC - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by StockNews.com to “Strong-Buy” Rating - Defense World
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses. - ACCESS Newswire
Thrivent Financial for Lutherans Sells 591 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Teacher Retirement System of Texas Has $591,000 Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
ATTENTION SUPN SHAREHOLDERS: Investors who lost money on Supernus Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Swiss National Bank - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Buy” Rating by StockNews.com - Defense World
11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLC - Defense World
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN) - ACCESS Newswire
Raymond James Financial Inc. Takes $6.85 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Raymond James Financial Inc. Invests $6.85 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Armenian Reporter
(SUPN) Trading Report - news.stocktradersdaily.com
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Supernus Pharmaceuticals, Inc. Investment - ACCESS Newswire
PNC Financial Services Group Inc. Sells 362 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Atria Investments Inc Invests $288,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Charles Schwab Investment Management Inc. Purchases 40,968 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to “Strong-Buy” at StockNews.com - Defense World
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks - Yahoo Finance
Bank of New York Mellon Corp Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Where are the Opportunities in (SUPN) - news.stocktradersdaily.com
Smartleaf Asset Management LLC Has $47,000 Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Proficio Capital Partners LLC Acquires Shares of 11,282 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Spectrum Brands Holdings, Inc. (SPB): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Supernus to Participate in Two Upcoming Investor Conferences - GlobeNewswire
CNS Specialist Supernus Sets Investor Conference ScheduleWill You Hear What the CEO Has to Say? - StockTitan
Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses - accessnewswire.com
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals? - Yahoo Finance
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now? - Yahoo Finance
(SUPN) Technical Data - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc. - Defense World
Supernus Pharmaceuticals’ (SUPN) “Neutral” Rating Reiterated at Cantor Fitzgerald - Defense World
StockNews.com Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy - Defense World
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus.com
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Supernus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
What Questions Should Investors Ask Supernus CEO at Upcoming TD Cowen Conference? - StockTitan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Rhumbline Advisers - Defense World
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Enters Oversold Territory (SUPN) - Nasdaq
Supernus Pharmaceuticals Inc (SUPN) Reports Q4 2024 EPS of $0.27 - GuruFocus.com
Cantor maintains neutral on Supernus, price target at $36 By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):